ReviewCurrent psychiatry reports2007
Glutamate and anxiety disorders.
Review in Current psychiatry reports, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00805493 (Double-Blind Placebo-Controlled Trial of Riluzole in Pediatric Bipolar Disorder), which is not on this map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Double-Blind Placebo-Controlled Trial of Riluzole in Pediatric Bipolar Disorder
Who cites it
23 citing papers in PubMed, 47 citations in OpenAlex.
- Review
- Circulatory Metabolite Ratios as Indicators of Lifestyle Risk Factors Based on a Greek NAFLD Case-Control Study.Nutrients · 2024Article
- Role of Biosynthesis and Catabolism of Neurotransmitters in Drug Discovery for Anxiety and Depression.Current pharmaceutical design · 2024Review
- Blood glutamate scavenging as a novel glutamate-based therapeutic approach for post-traumatic brain injury anxiety and social impairment.Translational psychiatry · 2023Article
- Glutamate Neurotoxicity and Destruction of the Blood-Brain Barrier: Key Pathways for the Development of Neuropsychiatric Consequences of TBI and Their Potential Treatment Strategies.International journal of molecular sciences · 2022Review
- Acetylsalicylic acid reduces cigarette smoke withdrawal-induced anxiety in ratsFrontiers in pharmacology · 2022Article
- Peripheral role of glutamate in orofacial pain.Frontiers in neuroscience · 2022Review
- Unbiased Metabolomics Links Fatty Acid Pathways to Psychiatric Symptoms in People Living with HIV.Journal of clinical medicine · 2021Article
- Metabolomic signature of amino acids in plasma of patients with non-segmental Vitiligo.Metabolomics : Official journal of the Metabolomic Society · 2021Article
- Glutamate Systems in DSM-5 Anxiety Disorders: Their Role and a Review of Glutamate and GABA Psychopharmacology.Frontiers in psychiatry · 2020Review
- Blood glutamate scavenging as a novel glutamate-based therapeutic approach for post-stroke depression.Therapeutic advances in psychopharmacology · 2020Review
- Elucidating the putative link between prefrontal neurotransmission, functional connectivity, and affective symptoms in irritable bowel syndrome.Scientific reports · 2019Article
- Neuronal nitric oxide synthase and affective disorders.IBRO reports · 2018Review
- The novel cannabinoid receptor GPR55 mediates anxiolytic-like effects in the medial orbital cortex of mice with acute stress.Molecular brain · 2017Article
- Monosodium glutamate-associated alterations in open field, anxiety-related and conditioned place preference behaviours in mice.Naunyn-Schmiedeberg's archives of pharmacology · 2017Article
- Protein kinase C is essential for kainate-induced anxiety-related behavior and glutamatergic synapse upregulation in prelimbic cortex.CNS neuroscience & therapeutics · 2014Article
- The blockade of transient receptor potential ankirin 1 (TRPA1) signalling mediates antidepressant- and anxiolytic-like actions in mice.British journal of pharmacology · 2014Article
- Involvement of NMDA receptor complex in the anxiolytic-like effects of chlordiazepoxide in mice.Journal of neural transmission (Vienna, Austria : 1996) · 2011Article
- A behavioral and molecular analysis of ketamine in zebrafish.Synapse (New York, N.Y.) · 2011Article
- Potential psychiatric applications of metabotropic glutamate receptor agonists and antagonists.CNS drugs · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anxiety disorders are among the most prevalent psychiatric disorders, but they represent a particular challenge for treatment. The standard first-line treatments, including antidepressants, benzodiazepines, and buspirone, result in significant response rates for a majority of patients; however, unfavorable side effect profiles or risk for dependency for particular agents might limit their use by anxious patients, who often have low thresholds for medication discontinuation. Novel pharmacologic agents that modulate particular receptors, ion channels, or transporters relevant to glutamatergic neurotransmission may represent a new approach to the treatment of anxiety disorders, with generally more favorable side effect profiles. Although the role of glutamate in the pathophysiology of anxiety disorders is still being elucidated, the use of these agents in treatment of anxiety disorders and commonly comorbid conditions such as substance abuse and mood disorders will continue to increase.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.